Venus Remedies gets marketing approval for meropenem in Gulf

20 Nov 2013 Evaluate

Venus Remedies has emerged as the first Indian company to enter the generics market in the Gulf with marketing authorization for meropenem from the Saudi Food and Drug Authority (SFDA). The company is planning to launch this product in Saudi Arabia, considered one of the most lucrative pharmaceutical markets in the world, early next year.

Venus has become the first generic drug manufacturer in the world to get marketing approval for this product from the Gulf Cooperation Council (GCC). There is a $35 million market for meropenem in Saudi Arabia and the company is aiming at capturing 25% share in this market within the first year of the launch itself.

Meropenem is an off-patented antibacterial agent of the carbapenem class of antibiotics, which caters to diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.

Venus Remedies Share Price

292.05 -7.85 (-2.62%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.